Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LB1148 · 1 trial · 1 indication
• GI-2 is defined as the toleration of solid food and first bowel movement. * Ability to tolerate a solid oral diet is defined as the time from the end of surgery (the time of last skin staple or suture is placed by surgeon) to the time a patient finishes first solid meal that requires chewing and no significant nausea or vomiting for 4 hours after solid meal). * First bowel movement is defined as the time from the end of surgery to the first passage of stool.
| Arm | Type | Description |
|---|---|---|
| LB1148 | EXPERIMENTAL | active |
| Placebo | PLACEBO_COMPARATOR | placebo |
| Name | Type | Description |
|---|---|---|
| LB1148 | DRUG | A total of 700 mL of LB1148 will be administered orally as a split dose before surgery. |
| Placebo | DRUG | A total of 700 mL of placebo will be administered orally as a split dose before surgery. |
Inclusion Criteria: 1. Scheduled to undergo an elective (non-emergent) bowel resection with or without a planned stoma via laparotomy or minimally invasive technique. This includes any subject in which a resection of the small intestine, colon, or rectum is performed for any elected indication. 2. ...
LB1148 is an investigational small molecule being developed for ileus, a gastrointestinal condition. It is designed to help return gastrointestinal function and decrease post-operative ileus. The drug is currently in clinical development and has completed a Phase 2 trial.
The specific molecular target of LB1148 has not been disclosed. It is a small molecule being studied for its effects on gastrointestinal function, particularly in the context of post-operative ileus. The mechanism of action is not publicly detailed.
LB1148 is being developed by Genelux Corporation, a biopharmaceutical company traded on the stock exchange under the ticker symbol GNLX. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with ileus.
LB1148 is in Phase 2 of clinical development. A Phase 2 trial has been completed, which studied the drug for the return of gastrointestinal function and decrease of post-operative ileus. The drug is investigational and has not been approved by regulatory authorities.
LB1148 has one completed clinical trial registered as NCT05056935. This Phase 2 study evaluated the drug for return of gastrointestinal function and decrease of post-operative ileus. The trial enrolled 131 participants in China and was randomized, double-blind, and placebo-controlled.
No alternative names for LB1148 have been reported. The drug is known only by its development code LB1148 and is being studied by Genelux Corporation for the treatment of ileus.